Targeted Therapy & Precision Oncology
Part of Healthcare - Oncology
| Ticker | Company | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|
 LLY | Eli Lilly & Co. | $1.0t | $1123.00 | -0.2% | 4.1M |
 RVMD | Revolution Medicines, Inc. Common Stock | $33.5b | $149.20 | -4.2% | 2.1M |
 INCY | Incyte Genomics Inc | $19.3b | $102.39 | +1.1% | 2.6M |
 JAZZ | Jazz Pharmaceuticals, Inc. | $14.8b | $238.47 | -0.7% | 678.0K |
 EXEL | Exelixis Inc | $12.7b | $52.67 | +0.3% | 2.2M |
 NUVL | Nuvalent, Inc. Class A Common Stock | $8.7b | $90.84 | -3.4% | 716.0K |
 HALO | Halozyme Therapeutics, Inc. | $7.9b | $71.53 | -0.1% | 1.1M |
 CORT | Corcept Therapeutics Inc. | $7.5b | $72.63 | -3.0% | 774.7K |
 CELC | Celcuity Inc. Common Stock | $6.5b | $88.17 | -4.7% | 1.7M |
 COGT | Cogent Biosciences, Inc. Common Stock | $6.0b | $31.00 | -5.5% | 1.8M |
 ERAS | Erasca, Inc. Common Stock | $4.0b | $11.97 | -9.8% | 6.1M |
 TNGX | Tango Therapeutics, Inc. | $3.2b | $20.18 | -8.8% | 4.0M |
 RLAY | Relay Therapeutics, Inc. Common Stock | $3.1b | $13.52 | -7.0% | 6.1M |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | $2.6b | $28.30 | -3.2% | 710.9K |
 ELVN | Enliven Therapeutics, Inc. Common Stock | $2.5b | $34.71 | -2.2% | 1.1M |
 IMNM | Immunome, Inc. | $2.5b | $18.56 | -5.7% | 895.7K |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | $2.2b | $21.52 | -0.0% | 3.0M |
 TYRA | Tyra Biosciences, Inc. Common Stock | $2.0b | $26.64 | -2.0% | 1.5M |
 NVCR | NovoCure Limited Ordinary Shares | $2.0b | $17.17 | -4.6% | 2.2M |
 ZYME | Zymeworks Inc. | $1.8b | $24.04 | -4.3% | 464.8K |
 NRIX | Nurix Therapeutics, Inc. Common stock | $1.8b | $14.65 | -4.1% | 1.6M |
 GLUE | Monte Rosa Therapeutics, Inc. Common Stock | $1.7b | $16.36 | -5.8% | 950.3K |
 NUVB | Nuvation Bio Inc. | $1.7b | $4.73 | -8.5% | 3.5M |
 BHVN | Biohaven Ltd. | $1.7b | $10.86 | -4.7% | 2.0M |
 VIR | Vir Biotechnology, Inc. Common Stock | $1.6b | $8.64 | -5.6% | 1.3M |
 DMRA | Damora Therapeutics, Inc. Common Stock | $1.5b | $21.09 | -5.5% | 523.5K |
 AVBP | ArriVent BioPharma, Inc. Common Stock | $1.4b | $30.42 | -8.1% | 634.9K |
 URGN | UroGen Pharma Ltd. Ordinary Shares | $1.4b | $26.84 | -2.8% | 704.1K |
 OLMA | Olema Pharmaceuticals, Inc. Common Stock | $1.2b | $10.30 | -3.5% | 2.5M |
 KURA | Kura Oncology, Inc. | $0.9b | $8.74 | -0.3% | 3.2M |
 ORIC | Oric Pharmaceuticals, Inc. Common Stock | $0.9b | $7.50 | -6.5% | 1.2M |
 GERN | Geron Corp | $0.8b | $1.17 | -3.3% | 9.6M |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $0.8b | $5.95 | -5.7% | 1.3M |
 BBOT | BridgeBio Oncology Therapeutics, Inc. Common Stock | $0.7b | $7.82 | -5.0% | 306.6K |
 ARVN | Arvinas, Inc | $0.6b | $7.42 | -4.2% | 650.0K |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $0.6b | $29.98 | -0.9% | 498.4K |
 STRO | Sutro Biopharma, Inc. | $484.4m | $26.13 | -8.9% | 295.7K |
 CCCC | C4 Therapeutics, Inc. | $483.2m | $3.84 | -7.9% | 2.1M |
 MNPR | Monopar Therapeutics Inc. Common Stock | $435.7m | $59.76 | +0.3% | 193.3K |
 ADCT | ADC Therapeutics SA | $432.4m | $1.06 | -19.7% | 7.6M |
 VSTM | Verastem, Inc. | $380.5m | $3.70 | -4.2% | 3.0M |
 IMRX | Immuneering Corporation Class A Common Stock | $373.3m | $4.26 | -4.8% | 1.4M |
 DCTH | Delcath Systems Inc | $372.1m | $10.67 | -1.1% | 588.2K |
 PBYI | PUMA BIOTECHNOLOGY INC | $364.9m | $7.02 | +0.1% | 172.1K |
 PRLD | Prelude Therapeutics Incorporated | $312.2m | $3.82 | -6.4% | 220.9K |
 ZNTL | Zentalis Pharmaceuticals, Inc. Common Stock | $284.7m | $3.65 | -5.7% | 1.0M |
 NVCT | Nuvectis Pharma, Inc. Common Stock | $258.6m | $9.55 | -1.2% | 74.4K |
 WHWK | Whitehawk Therapeutics, Inc. Common Stock | $233.4m | $4.13 | -6.1% | 124.5K |
 TLSI | TriSalus Life Sciences, Inc. Common Stock | $209.4m | $3.17 | -4.1% | 304.4K |
 KPTI | Karyopharm Therapeutics Inc. | $206.2m | $9.08 | +0.1% | 262.5K |